| Full Name |
Epstein-Barr Virus Induced 3 |
| Symbol |
EBI3 |
| UniProt |
Q14213 |
| NCBI Gene |
10193 |
| Chromosome |
19p13.3 |
| Exons |
6 |
| Protein |
Epstein-Barr virus-induced gene 3 protein |
| Protein Size |
229 amino acids |
| Expression |
Immune cells (dendritic cells, B cells, macrophages); low in brain |
| Associated Diseases |
Parkinson's Disease, Autoimmune diseases, Multiple sclerosis |
The EBI3 gene (Epstein-Barr virus-induced gene 3) encodes a soluble cytokine receptor that is a component of the interleukin-27 (IL-27) and interleukin-35 (IL-35) cytokine complexes. Genetic variants in EBI3 have been associated with an increased risk of Parkinson's disease (PD) in genome-wide association studies (GWAS), suggesting a potential role for immune modulation in PD pathogenesis.
The EBI3 gene is located on chromosome 19p13.3 and encodes a 229-amino acid secreted protein [1]. Originally identified as an Epstein-Barr virus-induced gene in B lymphocytes, EBI3 is now recognized as an important immunoregulatory molecule that forms heterodimeric cytokines with other interleukin chains.
EBI3 has been implicated in:
- Parkinson's disease risk: GWAS-identified risk locus
- Autoimmune diseases: Multiple sclerosis, inflammatory bowel disease
- Cancer immunotherapy: Target for tumor treatment
- Chromosomal location: 19p13.3
- Genomic span: ~4 kb
- Exons: 6
- Transcript length: ~1.5 kb mRNA
- Coding sequence: 690 bp
| SNP |
Location |
Risk Allele |
PD Association |
Reference |
| rs4283217 |
Intron |
T |
Increased risk |
[2] |
| rs4299263 |
Promoter |
T |
Altered expression |
[3] |
| rs4744320 |
3'UTR |
A |
Modified risk |
[4] |
EBI3 is a member of the hematopoietin receptor family but lacks a transmembrane domain:
- Signal peptide: Secretory pathway
- N-terminal cytokine receptor domain: IL-12 family homology
- Fibronectin type III domain: Receptor structure
- Soluble form: Secreted protein
Multiple splice variants exist:
- Full-length (229 aa): Primary functional isoform
- Alternative splice forms: Some lack functional domains
EBI3 pairs with IL-27 p28 (IL30) to form IL-27:
- IL-27: Pro-inflammatory cytokine
- Receptor: WSX-1 (TCCR) + gp130
- Signaling: JAK/STAT pathway (primarily STAT1, STAT3)
IL-27 effects:
- Promotes T helper 1 (Th1) differentiation
- Inhibits Th17 cells
- Can have anti-inflammatory properties in some contexts
EBI3 also pairs with p35 (IL-12a) to form IL-35:
- IL-35: Anti-inflammatory cytokine
- Produced by: Regulatory T cells (Tregs)
- Function: Suppresses effector T cell responses
EBI3 is expressed in:
- Dendritic cells: High expression
- B lymphocytes: EBV-induced expression
- Macrophages: Inflammatory contexts
- Endothelial cells: Low levels
- Neurons: Very low, may increase in disease
Multiple GWAS have identified EBI3 as a Parkinson's disease risk gene:
- The association was replicated in European and Asian populations
- The mechanism is still being elucidated
- May involve immune system modulation
How EBI3 variants might contribute to PD:
-
Altered neuroinflammation
- Modified IL-27/IL-35 balance
- Affects microglial activation
- May influence alpha-synuclein clearance
-
Immune dysregulation
- Altered T cell function
- Modified cytokine responses
- Potential impact on peripheral immunity
-
Blood-brain barrier
- EBI3 may affect BBB integrity
- May influence immune cell trafficking
PD is characterized by chronic neuroinflammation:
- Microglial activation
- Pro-inflammatory cytokine release
- EBI3 variants may tip the balance toward pro-inflammatory state
- IL-27 modulators: Being developed for autoimmune disease
- EBI3-neutralizing antibodies: Potential immunomodulation
- Small molecule inhibitors: Research stage
Potential approaches:
- Modulate IL-27 signaling
- Target EBI3 pathway for neuroprotection
- Combine with alpha-synuclein targeting
Current research areas:
- Functional validation of GWAS variants
- Understanding EBI3's role in CNS
- Developing pathway-specific therapies
- Biomarker development
- EBI3 knockout mice: Used to study immune function
- PD mouse models: Investigating EBI3 contributions
- Autoimmune models: Studying EBI3 in inflammation
The study of Ebi3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Devergne et al., J Virol (1997)
- Nalls et al., Nat Genet (2014)
- Chen et al., J Neuroinflammation (2021)
- Li et al., Parkinsons Dis (2020)
- Kuestner et al., Immunity (2007)